ovarian cancer

Female, 40 years

The patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.

Continue reading on:

The patient underwent six surgeries, and after the latest recurrence, the tumor was deemed inoperable. Chemotherapy and hormone therapy attempts for two years proved ineffective, with further tumor progression noted. In 2016, the list of recommended drugs was fully exhausted, and DNA diagnostics (mutation analysis) did not identify any potentially effective targeted drugs.

Based on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.

Continue reading on:

Oncobox analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient’s disease.

Based on the comprehensive results from Oncobox Dx, a tyrosine kinase inhibitor (Sorafenib) was prescribed. There was a partial response to treatment with a significant reduction in tumor size, but the treatment was discontinued due to side effects. Additionally, a drug with a different mechanism of action (Imatinib) was selected, and a substantial reduction in tumor size over six months of treatment allowed for complete surgical removal. As of February 2021, the patient continues her treatment with no side effects and no signs of recurrence.

lung cancer

Male, 48 years

The patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.

Based on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient's condition and a progression-free survival of 2 years.

Continue reading on:

The patient underwent surgery and four subsequent courses of chemotherapy (Vinorelbine + Cisplatin). After eight months, brain metastases were discovered. He underwent radiation therapy, followed by receiving Ceritinib. After 21 months, cancer progression and the growth of brain metastases were detected. Over the next six months, the patient underwent three more varied treatments and received radio-surgery (cyberknife), but his condition continued to worsen, and new lung metastases were revealed.

Based on the Oncobox Dx results, a treatment regimen, including an ALK inhibitor, an angiogenesis inhibitor, and taxanes (Crizotinib + Bevacizumab + Docetaxel), was prescribed. The treatment resulted in a significant improvement in the patient's condition and a progression-free survival of 2 years.

Continue reading on:

Survival of our patient after developing resistance to ALK inhibitor was longer for 16 months than previously reported average survival for such cases.

stomach cancer

Female, 79 years

The patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.

Based on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.

Continue reading on:

The patient initially underwent chemotherapy (FOLFOX and FLOT regimens), which initially led to a reduction in tumor size. However, soon thereafter, she developed drug tolerance with no changes in tumor size. Doctors decided to switch to another treatment regimen.

Based on the Oncobox Dx results using the molecular profile of the tumor, a high response to immunotherapy was predicted. Oncologist decided to stop chemotherapy and proceed with surgery. After that, the patient received immunotherapy (Pembrolizumab) for 6 months, resulting in complete remission. No signs of recurrence have been observed for 2 years since starting immunotherapy.

Continue reading on:

"According to Oncobox results, the patient received immunotherapy with anti-PD1 therapy and is now free of disease for 2 years."

cholangiocarcinoma

Male, 72 years

The patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient's condition worsened.

Based on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient's condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.

Continue reading on:

The patient received four courses of chemotherapy (2 courses of Gemcitabine + Cisplatin followed by 2 courses of Gemcitabine + Capecitabine). Despite adherence to clinical guidelines for treatment, tumor progression was observed, and the patient's condition worsened.

Based on the comprehensive Oncobox Dx results, a tyrosine kinase inhibitor (Sorafenib) was prescribed. Sorafenib monotherapy led to tumor stabilization and significant pain reduction. After 6 months, tumor progression was detected, and the patient was prescribed another tyrosine kinase inhibitor (Pazopanib), also selected by Oncobox. This change in the treatment regimen alleviated the side effects of Sorafenib, improved the patient's condition, and showed positive changes in lab test results. Worldwide statistics indicate that the survival rate for cholangiocarcinoma patients is typically no more than 6 months. However, thanks to personalized treatment selection by Oncobox, the patient lived for more than two years and maintained physical activity.

Continue reading on:

"After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy."